<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medecol</journal-id><journal-title-group><journal-title xml:lang="ru">Медицина и экология</journal-title><trans-title-group xml:lang="en"><trans-title>Medicine and ecology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-6045</issn><issn pub-type="epub">2305-6053</issn><publisher><publisher-name>Карагандинский медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.59598/ME-2305-6053-2026-119-2-125-135</article-id><article-id custom-type="elpub" pub-id-type="custom">medecol-1342</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Продольное прогрессирование инвалидизации, определяемой по шкале EDSS, у пациентов с рассеянным склерозом: данные азербайджанской когорты</article-title><trans-title-group xml:lang="en"><trans-title>Longitudinal progression of disability defined by the EDSS scale in patients with multiple sclerosis: data from the Azerbaijani cohort</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиев</surname><given-names>Р. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Aliyev</surname><given-names>R. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рагим Рафаил оглы Алиев</p><p>AZ1022, г. Баку, ул. А. Бакыханова, 23</p></bio><bio xml:lang="en"><p>Rahim Rafail oglu Aliyev</p><p>AZ1022, Baku c., A. Bakikhanova str., 23</p></bio><email xlink:type="simple">drrahimaliyev@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ширалиева</surname><given-names>Р. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Shiraliyeva</surname><given-names>R. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>AZ1012, г. Баку, ул. М. Гасанова, 35</p></bio><bio xml:lang="en"><p>AZ1012, Baku c., M. Hasanova str., 35</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кафедра неврологии Азербайджанского медицинского университета</institution><country>Азербайджан</country></aff><aff xml:lang="en"><institution>Department of Neurology, Azerbaijan Medical University</institution><country>Azerbaijan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кафедра неврологии и клинической нейрофизиологии Азербайджанского государственного института усовершенствования врачей им. А. Алиева</institution><country>Азербайджан</country></aff><aff xml:lang="en"><institution>Department of Neurology and Clinical Neurophysiology, Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev</institution><country>Azerbaijan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>15</day><month>08</month><year>2026</year></pub-date><volume>0</volume><issue>2</issue><fpage>125</fpage><lpage>135</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Алиев Р.Р., Ширалиева Р.К., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Алиев Р.Р., Ширалиева Р.К.</copyright-holder><copyright-holder xml:lang="en">Aliyev R.R., Shiraliyeva R.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medecol.qmu.kz/jour/article/view/1342">https://medecol.qmu.kz/jour/article/view/1342</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить продольные изменения инвалидизации, определяемой по шкале EDSS, от момента установления диагноза до конца периода наблюдения, а также изучить переходы между категориями инвалидизации и их связь с длительностью заболевания у пациентов с рассеянным склерозом в Азербайджане.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Было проведено продольное наблюдательное исследование с ретроспективным и проспективным компонентами за 2013 2022 гг. В анализ были включены 238 пациентов с подтвержденным рассеянным склерозом, у которых имелись данные EDSS при постановке диагноза и к концу исследования. Инвалидизация была классифицирована как легкая (EDSS 0-3,5), умеренная (4,0-6,5) и тяжелая (7,0-9,5). Использовались критерий знаковых рангов Уилкоксона, критерий χ² Пирсона, коэффициент V Крамера, критерий Краскела Уоллиса и U-критерий Манна Уитни.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. При постановке диагноза легкая инвалидизация была выявлена у 189 (79,4%) пациентов, умеренная у 49 (20,6%). К концу исследования доля легкой инвалидизации снизилась до 41,6%, доля умеренной увеличилась до 43,3%, тяжелая инвалидизация сформировалась у 15,1% пациентов. Медиана EDSS повысилась с 2,0 [1,0 3,0] до 4,3 [3,0 6,0], медиана ΔEDSS составила 2,5 [1,0 3,0] (p=&lt;0,001). Исходная категория EDSS была тесно связана с конечным уровнем инвалидизации (χ²(2)=104,935; p&lt;0,001; Cramer’s V=0,664). Большая длительность заболевания ассоциировалась с переходом в более тяжелые категории EDSS.</p></sec><sec><title>Выводы</title><p>Выводы. У пациентов с рассеянным склерозом в Азербайджане было отмечено значимое прогрессирование EDSS. Исходный EDSS и длительность заболевания могут рассматриваться как практические показатели риска последующей инвалидизации.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To assess longitudinal changes in disability defined by the EDSS scale from the time of diagnosis to the end of the follow-up period, as well as to study transitions between disability categories and their association with disease duration in patients with multiple sclerosis in Azerbaijan.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A longitudinal observational study with retrospective and prospective components was conducted for 2013 2022. The analysis included 238 patients with confirmed multiple sclerosis who had EDSS data at diagnosis and at the end of the study. Disability was classified as mild (EDSS 0 3.5), moderate (4.0 6.5), and severe (7.0 9.5). The Wilcoxon signed-rank test, Pearson’s χ[<xref ref-type="bibr" rid="cit2">2</xref>] test, Cramer’s V coefficient, Kruskal Wallis test, and Mann Whitney U test were used.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. At diagnosis, mild disability was identified in 189 (79.4%) patients, and moderate disability in 49 (20.6%). By the end of the study, the proportion of mild disability decreased to 41.6%, moderate disability increased to 43.3%, and severe disability developed in 15.1% of patients. The median EDSS increased from 2.0 [1.0 3.0] to 4.3 [3.0 6.0], and the median ΔEDSS was 2.5 [1.0 3.0] (p&lt;0.001). The baseline EDSS category was closely associated with the final level of disability (χ[<xref ref-type="bibr" rid="cit2">2</xref>] (2)=104.935; p&lt;0.001; Cramer’s V=0.664). Longer disease duration was associated with transition to more severe EDSS categories.</p></sec><sec><title>Conclusions </title><p>Conclusions . Significant EDSS progression was observed in patients with multiple sclerosis in Azerbaijan. Baseline EDSS and disease duration may be considered practical indicators of the risk of subsequent disability.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>EDSS</kwd><kwd>инвалидизация</kwd><kwd>прогрессирование</kwd><kwd>Азербайджан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>EDSS</kwd><kwd>disability</kwd><kwd>progression</kwd><kwd>Azerbaijan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Achiron A., Dreyer-Alster S., Gurevich M., Menascu S., Magalashvili D., Dolev M., Stern Y., ZivBaran T. Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. Mult. Scler. Relat. Disord. 2021; 50: 102814. https://doi.org/10.1016/j.msard.2021.102814</mixed-citation><mixed-citation xml:lang="en">Achiron A., Dreyer-Alster S., Gurevich M., Menascu S., Magalashvili D., Dolev M., Stern Y., ZivBaran T. Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. Mult. Scler. Relat. Disord. 2021; 50: 102814. https://doi.org/10.1016/j.msard.2021.102814</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Amatya B., Khan F., Galea M. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. 2019; 1 (1): CD012732. https://doi.org/10.1002/14651858.CD012732.pub2</mixed-citation><mixed-citation xml:lang="en">Amatya B., Khan F., Galea M. Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. 2019; 1 (1): CD012732. https://doi.org/10.1002/14651858.CD012732.pub2</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Arsoy E., Bulut N., Pamuk S., Türkoğlu R. The Multiple Sclerosis Functional Composite (MSFC) for Determining Disease Progression: A Methodological Study. Journal of Multiple Sclerosis Research . 2022; 2: 5-12. https://doi.org/10.4274/jmsr.galenos.2022.2022-3-1</mixed-citation><mixed-citation xml:lang="en">Arsoy E., Bulut N., Pamuk S., Türkoğlu R. The Multiple Sclerosis Functional Composite (MSFC) for Determining Disease Progression: A Methodological Study. Journal of Multiple Sclerosis Research . 2022; 2: 5-12. https://doi.org/10.4274/jmsr.galenos.2022.2022-3-1</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bau L., Matas E., Romero-Pinel L., León I. et al. Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort. Neurological Sciences . 2025; 46: 335-342. https://doi.org/10.1007/s10072-024-07767-3</mixed-citation><mixed-citation xml:lang="en">Bau L., Matas E., Romero-Pinel L., León I. et al. Assessment of the Multiple Sclerosis Severity Score and the Age-Related Multiple Sclerosis Severity Score as health indicators in a population-based cohort. Neurological Sciences . 2025; 46: 335-342. https://doi.org/10.1007/s10072-024-07767-3</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bostan M., Pîrvulescu R., Tiu C., Bujor I., Popa-Cherecheanu A. OCT and OCT-A biomarkers in multiple sclerosis review. Rom. J. Ophthalmol. 2023; 67 (2): 107-110. https://doi.org/10.22336/ rjo.2023.20</mixed-citation><mixed-citation xml:lang="en">Bostan M., Pîrvulescu R., Tiu C., Bujor I., Popa-Cherecheanu A. OCT and OCT-A biomarkers in multiple sclerosis review. Rom. J. Ophthalmol. 2023; 67 (2): 107-110. https://doi.org/10.22336/ rjo.2023.20</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Brown J. W.L., Coles A., Horakova D., Havrdova E. et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA . 2019; 321: 175. https://doi.org/10.1001/jama.2018.20588</mixed-citation><mixed-citation xml:lang="en">Brown J. W.L., Coles A., Horakova D., Havrdova E. et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA . 2019; 321: 175. https://doi.org/10.1001/jama.2018.20588</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Conradsson D., Ytterberg C., von Koch L., Johansson S. Changes in disability in people with multiple sclerosis: a 10-year prospective study. Journal of Neurology . 2018; 265: 119-126. https://doi.org/10.1007/s00415-017-8676-8</mixed-citation><mixed-citation xml:lang="en">Conradsson D., Ytterberg C., von Koch L., Johansson S. Changes in disability in people with multiple sclerosis: a 10-year prospective study. Journal of Neurology . 2018; 265: 119-126. https://doi.org/10.1007/s00415-017-8676-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz Rivera S., Aiyegbusi O.L., Piani Meier D., Dunne A. et al. The effect of disease modifying therapies on fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders . 2023; 79: 105065. https://doi.org/10.1016/j.msard.2023.105065</mixed-citation><mixed-citation xml:lang="en">Cruz Rivera S., Aiyegbusi O.L., Piani Meier D., Dunne A. et al. The effect of disease modifying therapies on fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders . 2023; 79: 105065. https://doi.org/10.1016/j.msard.2023.105065</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">De Meo E., Addazio I., Portaccio E., Bonacchi R. et al. Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments. Neurology . 2025; 105(12): e214408. https://doi.org/10.1212/WNL.0000000000214408</mixed-citation><mixed-citation xml:lang="en">De Meo E., Addazio I., Portaccio E., Bonacchi R. et al. Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments. Neurology . 2025; 105(12): e214408. https://doi.org/10.1212/WNL.0000000000214408</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Demir S. Expanded Disability Status Scale (EDSS) in Multiple Sclerosis. Cam and Sakura Medical Journal . 2022; 2: 82-89. https://doi.org/10.4274/csmedj.galenos.2022.2022-11-11</mixed-citation><mixed-citation xml:lang="en">Demir S. Expanded Disability Status Scale (EDSS) in Multiple Sclerosis. Cam and Sakura Medical Journal . 2022; 2: 82-89. https://doi.org/10.4274/csmedj.galenos.2022.2022-11-11</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Di Filippo M., Gaetani L., Centonze D., Hegen H. et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg Health Eur. 2024; 44: 101009. https://doi.org/10.1016/j.lanepe.2024.101009</mixed-citation><mixed-citation xml:lang="en">Di Filippo M., Gaetani L., Centonze D., Hegen H. et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg Health Eur. 2024; 44: 101009. https://doi.org/10.1016/j.lanepe.2024.101009</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dobson R., Giovannoni G. Multiple sclerosis a review. Journal of Neurology . 2019; 26: 2740. https://doi.org/10.1111/ene.13819</mixed-citation><mixed-citation xml:lang="en">Dobson R., Giovannoni G. Multiple sclerosis a review. Journal of Neurology . 2019; 26: 2740. https://doi.org/10.1111/ene.13819</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine . 2020; 20: 380-383. https://doi.org/10.7861/clinmed.2020-0292</mixed-citation><mixed-citation xml:lang="en">Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine . 2020; 20: 380-383. https://doi.org/10.7861/clinmed.2020-0292</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Greco G., Rigoni E., Masi F., Cosentino G. et al. The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria. Multiple Sclerosis Journal . Mult Scler. 2026; 32 (5): 465-474. https://doi.org/10.1177/13524585261424125</mixed-citation><mixed-citation xml:lang="en">Greco G., Rigoni E., Masi F., Cosentino G. et al. The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria. Multiple Sclerosis Journal . Mult Scler. 2026; 32 (5): 465-474. https://doi.org/10.1177/13524585261424125</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hartung D.M. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther. Adv. Neurol. Disord. 2021; 14: 1756286420987031. https://doi.org/10.1177/1756286420987031</mixed-citation><mixed-citation xml:lang="en">Hartung D.M. Health economics of disease-modifying therapy for multiple sclerosis in the United States. Ther. Adv. Neurol. Disord. 2021; 14: 1756286420987031. https://doi.org/10.1177/1756286420987031</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Iaffaldano P., Lucisano G., Guerra T., Caputo F. et al. Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis. Annals of Clinical and Translational Neurology . 2025; 12: 2012-2019. https://doi.org/10.1002/acn3.70131</mixed-citation><mixed-citation xml:lang="en">Iaffaldano P., Lucisano G., Guerra T., Caputo F. et al. Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis. Annals of Clinical and Translational Neurology . 2025; 12: 2012-2019. https://doi.org/10.1002/acn3.70131</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Inojosa H., Schriefer D., Ziemssen T. Clinical outcome measures in multiple sclerosis: A review. Autoimmunity Reviews . 2020; 19: 102512. https://doi.org/10.1016/j.autrev.2020.102512</mixed-citation><mixed-citation xml:lang="en">Inojosa H., Schriefer D., Ziemssen T. Clinical outcome measures in multiple sclerosis: A review. Autoimmunity Reviews . 2020; 19: 102512. https://doi.org/10.1016/j.autrev.2020.102512</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jakimovski D., Kavak K.S., Vaughn C.B., Goodman A.D. et al. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders . 2022; 57: 103406. https://doi.org/10.1016/j.msard.2021.103406</mixed-citation><mixed-citation xml:lang="en">Jakimovski D., Kavak K.S., Vaughn C.B., Goodman A.D. et al. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age. Multiple Sclerosis and Related Disorders . 2022; 57: 103406. https://doi.org/10.1016/j.msard.2021.103406</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Jakimovski D., Bittner S., Zivadinov R., Morrow S.A. et al. Multiple sclerosis. The Lancet . 2024; 403: 183-202. https://doi.org/10.1016/S01406736(23)01473-3</mixed-citation><mixed-citation xml:lang="en">Jakimovski D., Bittner S., Zivadinov R., Morrow S.A. et al. Multiple sclerosis. The Lancet . 2024; 403: 183-202. https://doi.org/10.1016/S01406736(23)01473-3</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kister I., Kantarci O.H. Multiple Sclerosis Severity Score: Concept and applications. Multiple Sclerosis Journal . 2020; 26: 548-553. https://doi.org/10.1177/1352458519880125</mixed-citation><mixed-citation xml:lang="en">Kister I., Kantarci O.H. Multiple Sclerosis Severity Score: Concept and applications. Multiple Sclerosis Journal . 2020; 26: 548-553. https://doi.org/10.1177/1352458519880125</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhlmann T., Antel J. Multiple sclerosis: 2023 update. Free Neuropathol. 2023; 4: 3. https://doi.org/10.17879/freeneuropathology-2023-4675</mixed-citation><mixed-citation xml:lang="en">Kuhlmann T., Antel J. Multiple sclerosis: 2023 update. Free Neuropathol. 2023; 4: 3. https://doi.org/10.17879/freeneuropathology-2023-4675</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kurtzke J.F. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurologica Scandinavica . 1970; 46: 493-512. https://doi.org/10.1111/j.1600-0404.1970.tb05808.x</mixed-citation><mixed-citation xml:lang="en">Kurtzke J.F. Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurologica Scandinavica . 1970; 46: 493-512. https://doi.org/10.1111/j.1600-0404.1970.tb05808.x</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Marrie R.A., McFadyen C., Yaeger L., Salter A. A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale. International Journal of MS Care . 2023; 25: 20-25. https://doi.org/10.7224/1537-2073.2021-102</mixed-citation><mixed-citation xml:lang="en">Marrie R.A., McFadyen C., Yaeger L., Salter A. A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale. International Journal of MS Care . 2023; 25: 20-25. https://doi.org/10.7224/1537-2073.2021-102</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Momsen A.H., Ørtenblad L., Maribo T. Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews. Annals of Physical and Rehabilitation Medicine . 2022; 65: 101529. https://doi.org/10.1016/j.rehab.2021.101529</mixed-citation><mixed-citation xml:lang="en">Momsen A.H., Ørtenblad L., Maribo T. Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews. Annals of Physical and Rehabilitation Medicine . 2022; 65: 101529. https://doi.org/10.1016/j.rehab.2021.101529</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE guideline NG220 . https://www.nice.org.uk/guidance/ng220</mixed-citation><mixed-citation xml:lang="en">National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. NICE guideline NG220 . https://www.nice.org.uk/guidance/ng220</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011; 69 (2): 292-302. https://doi.org/10.1002/ana.22366</mixed-citation><mixed-citation xml:lang="en">Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O’Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011; 69 (2): 292-302. https://doi.org/10.1002/ana.22366</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Purmonen T., Hakkarainen T., Tervomaa M., Ruutiainen J. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J. Med. Econ. 2020; 23 (2): 156-165. https://doi.org/10.1080/13696 998.2019.1682004</mixed-citation><mixed-citation xml:lang="en">Purmonen T., Hakkarainen T., Tervomaa M., Ruutiainen J. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J. Med. Econ. 2020; 23 (2): 156-165. https://doi.org/10.1080/13696 998.2019.1682004</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Quevillon T., Despault P.O., Duquette P., Girard M., Prat A., Larochelle C., Macaron G., Cusson A., Ducruet T. Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry. Rev. Neurol (Paris). 2026; 182 (4): 301-311. https://doi.org/10.1016/j.neurol.2026.02.154</mixed-citation><mixed-citation xml:lang="en">Quevillon T., Despault P.O., Duquette P., Girard M., Prat A., Larochelle C., Macaron G., Cusson A., Ducruet T. Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry. Rev. Neurol (Paris). 2026; 182 (4): 301-311. https://doi.org/10.1016/j.neurol.2026.02.154</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Rossi R.J. Applied Biostatistics for the Health Sciences . Hoboken (NJ): Wiley; 2022: 688.</mixed-citation><mixed-citation xml:lang="en">Rossi R.J. Applied Biostatistics for the Health Sciences . Hoboken (NJ): Wiley; 2022: 688.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sempik I., Dziadkowiak E., Moreira H., Zimny A., Pokryszko-Dragan A. Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression. Int. J. Mol. Sci. 2024; 25 (16): 8751. https://doi.org/10.3390/ijms25168751</mixed-citation><mixed-citation xml:lang="en">Sempik I., Dziadkowiak E., Moreira H., Zimny A., Pokryszko-Dragan A. Primary Progressive Multiple Sclerosis-A Key to Understanding and Managing Disease Progression. Int. J. Mol. Sci. 2024; 25 (16): 8751. https://doi.org/10.3390/ijms25168751</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sotiropoulos M.G., Lokhande H., Healy B.C., Polgar-Turcsanyi M., Glanz B.I., Bakshi R., Weiner H.L., Chitnis T. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult. Scler. J. Exp. Transl. Clin. 2021; 7 (2): 20552173211015503. https://doi.org/10.1177/20552173211015503</mixed-citation><mixed-citation xml:lang="en">Sotiropoulos M.G., Lokhande H., Healy B.C., Polgar-Turcsanyi M., Glanz B.I., Bakshi R., Weiner H.L., Chitnis T. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult. Scler. J. Exp. Transl. Clin. 2021; 7 (2): 20552173211015503. https://doi.org/10.1177/20552173211015503</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Suknjaja V., Sakalaš L., Ilin M. Early onset of multiple sclerosis clinical features. Acta Clin. Croat. 2024; 63 (1): 23-28. https://doi.org/10.20471/acc.2024.63.01.3</mixed-citation><mixed-citation xml:lang="en">Suknjaja V., Sakalaš L., Ilin M. Early onset of multiple sclerosis clinical features. Acta Clin. Croat. 2024; 63 (1): 23-28. https://doi.org/10.20471/acc.2024.63.01.3</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Taslim N., Aqil M., Jbeen A., Ahmad S., Siddiqi A. Current trends and prospects of multiple sclerosis research in Arab countries. East Mediterr. Health J. 2022; 28 (12): 863-871. https://doi.org/10.26719/emhj.22.092</mixed-citation><mixed-citation xml:lang="en">Taslim N., Aqil M., Jbeen A., Ahmad S., Siddiqi A. Current trends and prospects of multiple sclerosis research in Arab countries. East Mediterr. Health J. 2022; 28 (12): 863-871. https://doi.org/10.26719/emhj.22.092</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17 (2): 162-173. https://doi.org/10.1016/S1474-4422(17)30470-2</mixed-citation><mixed-citation xml:lang="en">Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17 (2): 162-173. https://doi.org/10.1016/S1474-4422(17)30470-2</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Uher T., Adzima A., Srpova B., Noskova L. et al. Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences. Mult. Scler. 2023; 29 (11-12): 1437-1451. https://doi.org/10.1177/13524585231197076</mixed-citation><mixed-citation xml:lang="en">Uher T., Adzima A., Srpova B., Noskova L. et al. Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences. Mult. Scler. 2023; 29 (11-12): 1437-1451. https://doi.org/10.1177/13524585231197076</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Valizadeh A., Moassefi M., Barati E., Ali Sahraian M., Aghajani F., Fattahi M.R. Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis. CNS Neurosci. Ther. 2021; 27 (11): 1268-1280.</mixed-citation><mixed-citation xml:lang="en">Valizadeh A., Moassefi M., Barati E., Ali Sahraian M., Aghajani F., Fattahi M.R. Correlation between the clinical disability and T1 hypointense lesions’ volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis. CNS Neurosci. Ther. 2021; 27 (11): 1268-1280.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zanghì A., Copetti M., Avolio C., Paolicelli D. et al. Multiple sclerosis from onset to secondary progression: a 30-year Italian register study. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2025; 96: 1061-1069. https://doi.org/10.1136/jnnp-2025335958</mixed-citation><mixed-citation xml:lang="en">Zanghì A., Copetti M., Avolio C., Paolicelli D. et al. Multiple sclerosis from onset to secondary progression: a 30-year Italian register study. Journal of Neurology, Neurosurgery &amp; Psychiatry . 2025; 96: 1061-1069. https://doi.org/10.1136/jnnp-2025335958</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Dağınıq sklerozun diaqnostika vә müalicәsi üzrә klinik protokol. 2-ci nәşr, yenilәnmiş. Bakı: Azәrbaycan Respublikasının Sәhiyyә Nazirliyi; 2022: 56.</mixed-citation><mixed-citation xml:lang="en">Dağınıq sklerozun diaqnostika vә müalicәsi üzrә klinik protokol. 2-ci nәşr, yenilәnmiş. Bakı: Azәrbaycan Respublikasının Sәhiyyә Nazirliyi; 2022: 56.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Dağınıq sklerozun diaqnostika vә müalicәsi üzrә klinik protokol. Bakı: Azәrbaycan Respublikasının Sәhiyyә Nazirliyi; 2013: 40.</mixed-citation><mixed-citation xml:lang="en">Dağınıq sklerozun diaqnostika vә müalicәsi üzrә klinik protokol. Bakı: Azәrbaycan Respublikasının Sәhiyyә Nazirliyi; 2013: 40.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Şirәliyeva R.K., Memiş A., Mirzәyev A.H., Әliyev R.R. Dağınıq skleroz zamanı baş beynin atrofiyası ilә klinik simptomlar arasında korrelyasiyalar. Azәrbaycan tibb jurnalı. 2020; 2: 47-50. https://doi.org/10.34921/amj.2020.2.007</mixed-citation><mixed-citation xml:lang="en">Şirәliyeva R.K., Memiş A., Mirzәyev A.H., Әliyev R.R. Dağınıq skleroz zamanı baş beynin atrofiyası ilә klinik simptomlar arasında korrelyasiyalar. Azәrbaycan tibb jurnalı. 2020; 2: 47-50. https://doi.org/10.34921/amj.2020.2.007</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
